Literature DB >> 29700170

Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era.

Anthony Mato1, Jordan Jahnke2, Pengxiang Li2,3, Maneesha Mehra4, Vrushabh P Ladage2, Michelle Mahler5, Scott Huntington6, Jalpa A Doshi7,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29700170      PMCID： PMC6165790          DOI： 10.3324/haematol.2017.185868

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Authors:  M Hallek; K Fischer; G Fingerle-Rowson; A M Fink; R Busch; J Mayer; M Hensel; G Hopfinger; G Hess; U von Grünhagen; M Bergmann; J Catalano; P L Zinzani; F Caligaris-Cappio; J F Seymour; A Berrebi; U Jäger; B Cazin; M Trneny; A Westermann; C M Wendtner; B F Eichhorst; P Staib; A Bühler; D Winkler; T Zenz; S Böttcher; M Ritgen; M Mendila; M Kneba; H Döhner; S Stilgenbauer
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

2.  Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century.

Authors:  Hermann Brenner; Adam Gondos; Dianne Pulte
Journal:  Blood       Date:  2008-02-28       Impact factor: 22.113

Review 3.  Survival probabilities (the Kaplan-Meier method).

Authors:  J M Bland; D G Altman
Journal:  BMJ       Date:  1998-12-05

4.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

5.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

6.  An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.

Authors:  Mark D Danese; Robert I Griffiths; Michelle Gleeson; Sacha Satram-Hoang; Kevin Knopf; Joseph Mikhael; Carolina Reyes
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

7.  Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia.

Authors:  Natali Pflug; Jasmin Bahlo; Tait D Shanafelt; Barbara F Eichhorst; Manuela A Bergmann; Thomas Elter; Kathrin Bauer; Gebhart Malchau; Kari G Rabe; Stephan Stilgenbauer; Hartmut Döhner; Ulrich Jäger; Michael J Eckart; Georg Hopfinger; Raymonde Busch; Anna-Maria Fink; Clemens-Martin Wendtner; Kirsten Fischer; Neil E Kay; Michael Hallek
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

8.  Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force.

Authors:  R Stauder; B Eichhorst; M E Hamaker; K Kaplanov; V A Morrison; A Österborg; I Poddubnaya; J A Woyach; T Shanafelt; L Smolej; L Ysebaert; V Goede
Journal:  Ann Oncol       Date:  2017-02-01       Impact factor: 32.976

9.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

10.  Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.

Authors:  Sacha Satram-Hoang; Carolina Reyes; Khang Q Hoang; Faiyaz Momin; Sandra Skettino
Journal:  Ann Hematol       Date:  2014-03-18       Impact factor: 3.673
View more
  4 in total

1.  The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.

Authors:  Anthony Mato; Chadi Nabhan; Nicole Lamanna; Neil E Kay; David L Grinblatt; Christopher R Flowers; Charles M Farber; Matthew S Davids; Arlene S Swern; Kristen Sullivan; E Dawn Flick; Sarah M Gressett Ussery; Mecide Gharibo; Pavel Kiselev; Jeff P Sharman
Journal:  Blood Adv       Date:  2020-04-14

2.  Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.

Authors:  Joanna M Rhodes; Vincent A LoRe; Anthony R Mato; Elise A Chong; Jacqueline C Barrientos; James N Gerson; Stefan K Barta; Daniel J Landsburg; Sunita Dwivedy Nasta; Jakub Svoboda; Alison W Loren; Stephen J Schuster
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-02-27

3.  Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the medicare population.

Authors:  Ravi K Goyal; Saurabh P Nagar; Shaum M Kabadi; Hannah Le; Keith L Davis; James A Kaye
Journal:  Cancer Med       Date:  2021-03-18       Impact factor: 4.452

Review 4.  The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

Authors:  Tadeusz Robak; Magda Witkowska; Piotr Smolewski
Journal:  Cancers (Basel)       Date:  2022-02-02       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.